FIELD: biochemistry.
SUBSTANCE: invention relates to a monoclonal antibody or epitope-binding fragment thereof, capable of immunospecific binding to phosphorylated residue 396 of human tau protein, as well as to composition containing it.
EFFECT: invention provides effective therapeutic approach to taupathy.
3 cl, 34 dwg, 6 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES SPECIFIC TO HYPERPHOSPHORYLATED TAU-PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2760875C1 |
| MONOCLONAL ANTIBODIES TO ALPHA-SYNUCLEIN FOR PREVENTING TAU-PROTEIN AGGREGATION | 2017 |
|
RU2760334C2 |
| ANTI-TAU PROTEIN ANTIBODIES AND METHODS OF USING SAID ANTIBODIES | 2016 |
|
RU2732122C2 |
| IMMUNOGENIC FUSED PROTEIN | 2016 |
|
RU2757426C2 |
| BISPECIFIC MOLECULES, IMMUNOREACTIVE WITH IMMUNE EFFECTOR CELLS EXPRESSING AN ACTIVATING RECEPTOR | 2014 |
|
RU2721707C2 |
| METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | 2018 |
|
RU2789485C2 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| ANTIBODIES TO PD-1 AND COMPOSITIONS | 2016 |
|
RU2750675C1 |
| COMBINED MEDICINAL PRODUCTS TARGETING PD-1, TIM-3 AND LAG-3 | 2018 |
|
RU2795232C2 |
| ANTI-LAG-3 ANTIBODIES AND THEIR COMPOSITIONS | 2017 |
|
RU2755503C2 |
